CAM
TGTX icon

Congress Asset Management’s TG Therapeutics TGTX Stock Holding History

Congress Asset Management’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$143M Buy
2,600,123
+432,042
+20% +$17.7M 0.88% 31
2026
Q1 		$72M Buy
2,168,081
+245,671
+13% +$7.32M 0.52% 74
2025
Q4 		$57.3M Buy
+1,922,410
New +$62.8M 0.4% 94

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Congress Asset Management's TGTX Position: Q2 2026 in Review

Congress Asset Management increased its TG Therapeutics (TGTX) stake by 20% in Q2 2026, buying an estimated $17.7M and bringing the position to 2,600,123 shares worth $143M. The position accounts for 0.88% of the portfolio, ranked #31.

Congress Asset Management first reported a position in TGTX in Q4 2025 and has held it in 3 quarters since. 427 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Congress Asset Management held 2,600,123 shares of TG Therapeutics worth $143M as of Q2 2026.
  • Congress Asset Management bought 432,042 TG Therapeutics shares in Q2 2026, an estimated $17.7M.
  • TG Therapeutics made up 0.88% of Congress Asset Management's portfolio in Q2 2026, its #31 holding.
  • Congress Asset Management first reported a position in TG Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 427 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Congress Asset Management's 13F filing for Q2 2026, filed 7 Jul 2026.